Gram-negative resistance is an increasingly important consideration when initiating empiric antimicrobial therapy in intensive care units. Infection with a resistant organism has been associated with increased morbidity and mortality as well as increased hospital cost. Gram-negative resistance in intensive care units will likely continue to increase. Clinicians must aggressively manage infections in the intensive care unit while practicing the appropriate steps to minimize future resistance. This review article summarizes the epidemiology, risk factors, mechanisms of resistance, and management of infections due to resistant gram-negative organisms.
Cohen ML. Epidemiology of drug resistance implications for a post-antimicrobial era. Science. 1992;257:1050-1055.
2.
Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America 2001). Int J Antimicrob Agents. 2004;24:111-118.
3.
National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992 through June 2003. Am J Infect Control. 2003;31:481-498.
4.
Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital acquired infection in the ICU patient. Crit Care Med. 1982;10:355-357.
5.
Clark NM, Patterson J, Lynch JP III. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care. 2003;9:413-423.
6.
Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units. JAMA. 2003;289:885-888.
7.
Vartivarian S, Anaissie E. Stenotrophomonas maltophilia and Burkholderia cepacia. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 5th ed.New York, NY: Churchill Livingstone; 2000:2335-2339.
8.
Vartivarian S, Anaissie E, Bodey C, et al.A changing pattern of susceptibility of Xanthamonas maltophilia to antibacterial agents: implications for therapy. Antimicrob Agents Chemother. 1994;38:624-627.
9.
Allen DM, Hartman BJ. Acinetobacter species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 5th ed.New York, NY: Churchill Livingstone; 2000:2339-2344.
10.
Hirai Y.Survival of bacteria under dry conditions: from a viewpoint of nosocomial infection. J Hosp Infect. 1991;19:191-200.
11.
Lorthorlary O, Fagon JY, Hoi AB, et al.Nosocomial acquisition of multiresistant acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis. 1995;20:790-796.
12.
International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest. 2001;120:955-970.
13.
Mahgoub S, Ahmed J, Glatt AE. Underlying characteristics of patients harboring highly resistant Acinetobacter baumanniiAm J Infect Control. 2002;30:386-390.
14.
Jain R, Danziger LH. Multi-resistant acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother. 2004;38:1449-1459.
15.
Urban C, Go E, Mariano N, et al.Effect of sulbactam on infections caused by imipenem-resistant acinetobacter calcoaceticus biotype anitratus. J Infect Dis. 1993;167:448-451.
16.
Chamber HF. Antimicrobial agents. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s: The Pharmacologic Basis of Therapeutics. 10th ed.New York, NY: McGraw-Hill; 2001:1261-1264.
17.
Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al.Treatment of multidrug-resistant Acinetobacter Baumannii (VAP) with intravenous colistin: a comparison with imipenem susceptible VAP. Clin Infect Dis. 2003;36:1111-1121.
18.
Levin AS, Barone AA, Penco J, et al.Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008-1011.
19.
Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents. 2003;21:58-62.
20.
Patterson J.Extended-spectrum beta-lactamases. Semin Resp Crit Care Med. 2003;24:79-87
21.
Lucet JC, Chevert S, Decre D, et al.Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis. 1996;22:430-436.
22.
Patterson DL, Ko WC, Gottberg AV, at al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. AnnInternMed. 2004;140:26-32.
23.
Patterson DL, Ko WC, Gottberg AV, et al.Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis. 2004;39:31-37.
24.
Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus enterobacteriaceae with potent β-lactamases. Antimicrob Agents Chemother. 2001;45:2831-2837.
25.
Pollack M.Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases.5th ed.NewYork, NY:Churchill Livingstone; 2000:2310-2335.
26.
Trouillet JL, Vuagnat A, Combes A, et al.Ventilator-associated pneumonia caused by potentially drug-resistant pathogens. Am J Respir Crit Care Med. 1998;157:531-539.
27.
Paramythiotou E, Lucet JC, Timsit JF, et al.Acquisition of multidrug resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis. 2004;38:670-677.
28.
Song W, Woo HJ, Kim JS, et al.In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosaInt J Antimicrob Agents. 2003;21:8-12.
29.
Linden PK, Kusne S, Coley K, et al.Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosaClin Infect Dis. 2003;37:154-160.
30.
Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146-155.
31.
Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462-474.
32.
Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262-268.
33.
Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V. Scheduled change of antibiotic classes. Am J Respir Crit Care Med. 1997;156:1040-1048.
34.
Niederman MS. Is “crop rotation” of antibiotic the solution to a “resistant” problem in the ICU?Am J Respir Crit Care Med. 1997;156:1029-1031.
35.
Rahal JJ, Urban C, Horn D, et al.Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial KlebsiellaJAMA. 1998;280:1233-1237.
36.
Burke JP. Antibiotic resistance: squeezing the balloon?JAMA. 1998;280:1270-1271.
37.
White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25:230-239.
38.
Cook PP, Catrou PG, Christie JD, Young PD, Polk RE. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother. 2004;53:853-859.
39.
Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med. 2004;32:1396-1405.
40.
Zack JE, Garrison T, Trovillion E, et al.Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. Crit Care Med. 2002;30:2407-2412.
41.
Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004;125:1791-1799.
42.
O’Grady NP, Alexander M, Dellinger EP, et al.Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. Morbidity & Mortality Weekly Report. Recommendations & Reports. 2002;151(RR-10):1-29. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5110.pdf.
43.
Cicalini S, Palmieri F, Petrosillo N. Clinical review: new technologies for prevention of intravascular catheter-related infections. Crit Care. 2003;7:1-6.
44.
Klibanov OM, Raasch RH, Rublein JC. Single versus combined antibiotic therapy for gram-negative infections. Ann Pharmacother. 2004;38:332-337.
45.
Pitout JD, Sanders CC, Sanders EW. Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. Am J Med. 1997;103:51-59.
Society for Healthcare Epidemiology of America and Infectious Disease Society of America Joint Committee on the Prevention of Antimicrobial Resistance. Guidelines for prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;25:584-599.
Centers for Disease Control and Prevention. Campaign to prevent antimicrobial resistance in healthcare settings. Available at: www.cdc.gov/drugresistance/healthcare.
